Results 1 to 10 of about 8,290,554 (306)

Cumulative corticosteroid burden over 25 years in patients initiating biologic therapy for severe asthma: a nationwide cohort study [PDF]

ERJ Open Research
Background Systemic corticosteroid use in severe asthma is associated with morbidity and mortality. Little is known about the long-term corticosteroid burden prior to biologic therapy.
Galathea Berner, Marianne Baastrup Soendergaard, Susanne Hansen, Anne-Sofie Bjerrum, Anna von Bülow, Ole Hilberg, Barbara Bonnesen, Claus Rikard Johnsen, Sofie Lock Johansson, Linda Makowska Rasmussen, Johannes Martin Schmid, Charlotte Suppli Ulrik, Celeste Porsbjerg, Kjell Erik Julius Håkansson   +13 more
doaj   +2 more sources

Assessment of Inhaled Corticosteroid Adherence in Adults with Severe Asthma Receiving Biologic Therapy: A Retrospective Observational Study [PDF]

Journal of Asthma and Allergy
Gökten Bulut,1 Derya Aydın2 1Department of Allergy and Immunology, Atatürk City Hospital, Balıkesir, Türkiye; 2Department of Chest Diseases, Atatürk City Hospital, Balıkesir, TürkiyeCorrespondence: Gökten Bulut ...
Bulut G, Aydın D
doaj   +2 more sources

Do Not Leave Your Patients in the Dark—Using American College of Rheumatology and European Alliance of Associations for Rheumatology Recommendations for Vaccination in Polish Adult Patients with Autoimmune Inflammatory Rheumatic Diseases

Vaccines, 2023
(1) Introduction: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) face a higher infectious risk compared to the general population. As per the ACR and EULAR recommendations, vaccinations against influenza, COVID-19, pneumococci, and ...
Jakub Wroński, Karolina Palej, Sandra Stańczyk, Marta Łosoś, Joanna Werońska-Tatara, Małgorzata Stasiek, Marta Wysmołek, Agnieszka Olech, Anna Felis-Giemza   +8 more
doaj   +1 more source

Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?

Pediatric Rheumatology Online Journal, 2023
Objective Approximately one third of children with JIA receive biologic therapy, but evidence on biologic therapy withdrawal is lacking. This study aims to increase our understanding of whether and when pediatric rheumatologists postpone a decision to ...
Janine A. van Til, Michelle M. A. Kip, Ellen J. H. Schatorjé, Gillian Currie, Marinka Twilt, Susanne M. Benseler, Joost F. Swart, Sebastiaan J. Vastert, Nico Wulffraat, Rae S. M. Yeung, C. G. M. (Karin) Groothuis-Oudshoorn, Sanne Warta, Deborah A. Marshall, Maarten J. IJzerman, on behalf of the UCAN CAN-DU, UCAN CURE consortia   +14 more
doaj   +1 more source

Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study

Arthritis Research & Therapy, 2022
Background To analyse the subsequent clinical course of patients with rheumatoid arthritis (RA) who either continued or discontinued biologic agents after hospitalization for infections.
Yusuke Kashiwado, Chikako Kiyohara, Yasutaka Kimoto, Shuji Nagano, Takuya Sawabe, Kensuke Oryoji, Shinichi Mizuki, Hiroaki Nishizaka, Seiji Yoshizawa, Shigeru Yoshizawa, Tomomi Tsuru, Yasushi Inoue, Naoyasu Ueda, Shun-ichiro Ota, Yasuo Suenaga, Tomoya Miyamura, Yoshifumi Tada, Hiroaki Niiro, Koichi Akashi, Takahiko Horiuchi   +19 more
doaj   +1 more source

Predicting Biologic Therapy Outcome of Patients With Spondyloarthritis: Joint Models for Longitudinal and Survival Analysis

JMIR Medical Informatics, 2021
BackgroundRheumatic diseases are one of the most common chronic diseases worldwide. Among them, spondyloarthritis (SpA) is a group of highly debilitating diseases, with an early onset age, which significantly impacts patients ...
Carolina Barata, Ana Maria Rodrigues, Helena Canhão, Susana Vinga, Alexandra M Carvalho   +4 more
doaj   +1 more source

Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD

BMC Pediatrics, 2021
Background The effect of biologic therapy on the incidence of inflammatory bowel disease (IBD)-related hospitalizations is controversial. The high efficacy of biologic agents is weighted against potential therapy-related adverse events, however, there ...
Gil Berkovitch, Shlomi Cohen, Ronit Lubetzky, Dana Singer, Anat Yerushalmy-Feler   +4 more
doaj   +1 more source

Biological therapies for spondyloarthritis [PDF]

Therapeutic Advances in Musculoskeletal Disease, 2014
Biological therapies and new imaging techniques have changed the therapeutic and diagnostic approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α (TNFα) inhibitor treatment is currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) has ...
Bruner V, Atteno M, Spanò A, SCARPA, RAFFAELE, PELUSO, ROSARIO   +4 more
openaire   +3 more sources

Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data

Pediatric Rheumatology Online Journal, 2021
Background Glucocorticoid exposure is a significant driver of morbidity in children with systemic juvenile idiopathic arthritis (sJIA). We determined the effect of early initiation of biologic therapy (IL-1 or IL-6 inhibition) on glucocorticoid exposure ...
Rosemary G. Peterson, Rui Xiao, Hannah Katcoff, Brian T. Fisher, Pamela F. Weiss   +4 more
doaj   +1 more source

Biologic therapy for dyslipidemia [PDF]

Vnitřní lékařství, 2021
Dyslipidemia treatment represents a very dynamically growing segment of pharmacotherapy, including a production of biological agents. Nowadays, they are targeting at various proteins that are involved in the synthesis, transport, or metabolism of lipoproteins.
openaire   +2 more sources